Rise in private testosterone prescribing risks overtreatment and more strain on the NHS
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
The rapid expansion of private testosterone prescribing risks extending treatment beyond men with clearly defined need to people with nonspecific symptoms and borderline test results, for whom the balance of benefit and long-term risk is less certain, warn experts in The BMJ.
Stephen Atkin and Eric Kilpatrick argue that the complexity of care is seldom covered in commercial testing, so managing the longer-term risks of testosterone therapy will likely fall to the NHS.
In 2024, the U.K. testosterone replacement market was valued at around $205 million and is projected to reach $365 million by 2032. NHS figures show community dispensing increased by 52% from 2020/21 to 2024/25 alongside a tenfold rise in testosterone gel prescriptions for women aged 50 and older in England between 2015 and 2022.
Private prescriptions are not recorded nationally, so the scale of private testosterone provision is unknown, explain the authors. However, several indicators suggest rapid growth: a proliferation of private and online clinics, subscription pricing of £100–£375 a month (to cover ongoing monitoring, remote consultations and home-delivered medication), and heavy marketing via social media, influencers and outdoor advertising.
The market is potentially large, they add. Declining testosterone and libido are natural aspects of aging, and up to a fifth of men over 50 may report deficiency symptoms, although under 1% receive treatment from the NHS.
Diagnosis takes time and repeated testing. It is not established how consistently private providers do this, but they warn that rapid-access subscription models built around marketing nonspecific symptoms "are unsuitable to handle the complexity of the diagnostic process and risk unnecessary lifelong treatment and a resulting NHS monitoring burden."
For testosterone therapy in men, clinicians rely on professional society guidance with differing thresholds, they write, meaning NHS clinicians may see patients who have already started taking testosterone against a more permissive private threshold.
They point to the longer-term risks of testosterone therapy, such as heart and kidney problems that need ongoing monitoring, which they say will likely fall to the NHS. There are also concerns about private off-label testosterone prescribing for women, mainly for low libido associated with menopause.
As stated in official guidance, the responsibility of care rests exclusively with any private-sector clinician who initiates treatment unless an NHS GP formally agrees to shared care, they explain. In practice, however, patients who started treatment privately may return to their GP informally for tests or to manage side effects, leading to the NHS absorbing the workload without any formal agreement.
The authors stress that testosterone replacement remains a valuable treatment for carefully selected patients, but say national data are needed to close the evidence gap on private prescribing of testosterone.
"A reporting framework for private prescribers and dispensing pharmacies could capture indications, patient numbers, monitoring and transfers of care," they write. "This would lead to transparent prescribing and demonstrable adherence to evidence-based care, protecting patients while preserving access to effective treatment."
Publication details
Implications of commercial testosterone prescribing for the NHS, The BMJ (2026). DOI: 10.1136/bmj-2026-101080
Journal information: British Medical Journal (BMJ)
Clinical categories
Men's healthClinical pharmacologyFamily medicineEndocrinologyWomen's healthHealthy aging Provided by British Medical Journal Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Rise in private testosterone prescribing risks overtreatment and more strain on the NHS (2026, October 14) retrieved 14 October 2026 from https://medicalxpress.com/news/2026-10-private-testosterone-overtreatment-strain-nhs.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.